Search results
Results from the WOW.Com Content Network
HIV disease–related drug reaction is an adverse drug reaction caused by drugs used for the treatment of HIV/AIDS. Image of common antiretroviral drugs to treat HIV infection [ 1 ] Drug reactions are a major cause of mortality and morbidity around the world.
The successful treatment and management of HIV/AIDS is affected by a plethora of factors which ranges from successfully taking prescribed medications, preventing opportunistic infection, and food access etc. Food insecurity is a condition in which households lack access to adequate food because of limited money or other resources.
Raltegravir (Isentress), developed by Merck & Co., was the first INSTI approved by the FDA in October 2007.; Elvitegravir (Vitekta), licensed by Gilead Sciences from Japan Tobacco, was approved by the U.S. Food and Drug Administration in August 2012, for use in adults starting HIV treatment for the first time as part of the fixed dose combination with emtricitabine and tenofovir disoproxil ...
Immune reconstitution inflammatory syndrome (IRIS) is a condition seen in some cases of HIV/AIDS or immunosuppression, in which the immune system begins to recover, but then responds to a previously acquired opportunistic infection with an overwhelming inflammatory response that paradoxically makes the symptoms of infection worse.
Stribild is not approved for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy of Stribild have not been established in patients coinfected with HBV and HIV-1.
Acquired immunodeficiency syndrome (AIDS) is defined as an HIV infection with either a CD4 + T cell count below 200 cells per μL or the occurrence of specific diseases associated with HIV infection. [32] In the absence of specific treatment, around half of people infected with HIV develop AIDS within ten years. [32]
Zalcitabine was the third antiretroviral to be approved by the Food and Drug Administration (FDA) for the treatment of HIV/AIDS. It is used as part of a combination regimen . Zalcitabine appears less potent than some other nucleoside RTIs, has an inconvenient three-times daily frequency and is associated with serious adverse events.
HIV drug resistance poses an issue because it reduces the possible HIV medications a person can take due to cross resistance. In cross resistance, an entire class of medication is considered ineffective in lowering a patient's HIV viral load because all the drugs in a given class share the same mechanism of action. [ 7 ]